Skip to content

Study · Randomized controlled trial · n = 296 · 2022

4 results

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.

Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á

The lancet. Diabetes & endocrinology22 Apr 2022Cited by 393 (Europe PMC)

PMID35468325 (opens in a new tab)DOI10.1016/s2213-8587(22)00070-5 (opens in a new tab)PepBankPUB-35468325
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and a fatty liver index of at least 60, pooled tirzepatide 10 mg and 15 mg reduced liver fat content at week 52 more than insulin degludec (-8·09% vs -3·38%; treatment difference -4·71%, 95% CI -6·72 to -2·70).

    In plain wordsIn adults with type 2 diabetes, liver fat fell more with tirzepatide than with insulin degludec after 52 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseChange in liver fat content (MRI-PDFF) at week 52
    Study

    n = 296

    Comparator
    Titrated insulin degludec (once daily, subcutaneous)
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    10 mg and 15 mg once weekly (pooled) · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    the absolute reduction in LFC at week 52 was significantly greater for the pooled tirzepatide 10 mg and 15 mg groups (-8·09%, SE 0·57) versus the insulin degludec group (-3·38%, 0·83). The estimated treatment difference versus insulin degludec was -4·71% (95% CI -6·72 to -2·70; p<0·0001).
    2 context sentences
    Summary · context
    296 (59%) of whom were included in the enrolled MRI population and randomly assigned to treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; and insulin degludec, n=74)
    Summary · context
    substudy participants had a fatty liver index of at least 60
  2. 02HumanRandomized controlled trialEfficacy outcome

    In the SURPASS-3 MRI substudy of adults with type 2 diabetes, tirzepatide significantly reduced visceral adipose tissue volume compared with insulin degludec.

    In plain wordsIn adults with type 2 diabetes, tirzepatide reduced belly (visceral) fat volume more than insulin degludec did.

    Peptide
    Tirzepatide
    Outcome
    DecreaseVisceral adipose tissue (VAT) volume
    Study

    n = 296

    Comparator
    Titrated insulin degludec (once daily, subcutaneous)
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    5 mg, 10 mg or 15 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide showed a significant reduction in LFC and VAT and ASAT volumes compared with insulin degludec in this subpopulation of patients with type 2 diabetes in the SURPASS-3 study.
    2 context sentences
    Summary · context
    296 (59%) of whom were included in the enrolled MRI population and randomly assigned to treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; and insulin degludec, n=74)
    Summary · context
    substudy participants had a fatty liver index of at least 60
  3. 03HumanRandomized controlled trialEfficacy outcome

    In the SURPASS-3 MRI substudy of adults with type 2 diabetes, tirzepatide significantly reduced abdominal subcutaneous adipose tissue volume compared with insulin degludec.

    In plain wordsIn adults with type 2 diabetes, tirzepatide reduced fat volume under the skin of the belly more than insulin degludec did.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAbdominal subcutaneous adipose tissue (ASAT) volume
    Study

    n = 296

    Comparator
    Titrated insulin degludec (once daily, subcutaneous)
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    5 mg, 10 mg or 15 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide showed a significant reduction in LFC and VAT and ASAT volumes compared with insulin degludec in this subpopulation of patients with type 2 diabetes in the SURPASS-3 study.
    2 context sentences
    Summary · context
    296 (59%) of whom were included in the enrolled MRI population and randomly assigned to treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; and insulin degludec, n=74)
    Summary · context
    substudy participants had a fatty liver index of at least 60
  4. 04HumanRandomized controlled trialMechanism

    In tirzepatide-treated adults with type 2 diabetes, the reduction in liver fat content was significantly correlated with baseline liver fat (ρ=-0·71) and with reductions in visceral fat, abdominal subcutaneous fat and body weight.

    In plain wordsIn people taking tirzepatide for type 2 diabetes, liver fat reduction was linked to starting liver fat and to reductions in abdominal fat and weight.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCorrelation of liver fat reduction with baseline liver fat, VAT, ASAT and body weight
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    5 mg, 10 mg or 15 mg once weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The reduction in LFC was significantly correlated (p≤0·0006) with baseline LFC (ρ=-0·71), reductions in VAT (ρ=0·29), reductions in ASAT (ρ=0·33), and reductions in body weight (ρ=0·34) in the tirzepatide groups.
    2 context sentences
    Summary · context
    296 (59%) of whom were included in the enrolled MRI population and randomly assigned to treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; and insulin degludec, n=74)
    Summary · context
    substudy participants had a fatty liver index of at least 60

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03882970

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 1,4441 Apr 2019 to 4 Jan 2021

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 19 Jan 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 12:39 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.